Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
Similar Posts
What are the Benefits of MICRODOSING Psilocybin? | Interview with a Microdosing Expert
What are the benefits of Microdosing psilocybin? | Interview with a Microdosing Expert
In today’s episode, we sit down with microdosing expert Sena Maria of The Medicine of Being Human and MicrodosingForResilience.com.
In this interview, we learn about Sena’s microdosing business, which helps people begin microdosing psilocybin (note she does not provide any illegal substances, only coaches people on how to microdose) and the benefits that microdosing can bring.
For example, Sena gives us a fantastic Top 5 Benefits of Microdosing at some point in our chat.
Some of the questions that we covered were:
-What is microdosing and what are the benefits?
-How/ why did you start microdosing ?
-What is your microdosing regiment?
-What benefits have you personally seen from this?
-What do you wish people knew about psychedelics that they don’t currently?
-Can Microdosing magic mushrooms help with addiction?
-Can microdosing help treat depression or anxiety?
On top of discussing the how and why of microdosing psychedelics, Sena also discussed how these medicines have been known for generations in some aboriginal tribes, and how Western Medicine may still have a lot to learn.
Timestamps
00:00- Intro
1:32 – Sena Maria’s journey to microdosing: From Google to Psychedelics
4:15- Microdosing For Resilience
5:58- How to microdose psilocybin
8:20- Top 5 benefits of Microdosing
13:31- What is missed in the psychedelics conversation?
18:34- Sena’s Psychedelic Ceremony experiences
22:05 – How did you integrate what you learned in your psychedelic ceremony
#Microdosing #MicrodosingBenefits #Psychedelics
Field Trip And Wesana Make Major Moves | FTRP, WESA
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Field Trip Press Release: https://www.globenewswire.com/news-
release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development
Field Trip Health:
In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.
Wesana:
On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.
@psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor
Will MindMed (MMED) join the NASDAQ? (What Will Happen To the Stock If It Does?)
Will MindMed get uplisted on the NASDAQ and what will happen to its stock price if the company is accepted? These are all questions we’ve been wondering 😱.
The requirements to join NASDAQ have been less than clear for investors. It has been more than six weeks since MindMed (MMED) applied for an uplisting on NASDAQ and retail investors have been waiting for news while MindMed’s stock price has been reaching all times highs🔥. In this video, we’ll discuss what the actual requirements are, what will happen to MMED’s stock price if the company gets uplisted, and whether retail investors should be influenced by the news ( good or bad).
Hope you guys enjoy this video!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock
Resources: https://www.thestreet.com/investing/nasdaq-listing-requirements-15092402?fbclid=IwAR09DXpV8nLoMgXrJ7Ru1A8GHk53BHQBakLFI1xnHLw-ZDzY7nZjp88D0CU
atai Life Sciences Q2 Conference Call and Questions & Answer Period: BIG NEWS for Psychedelic Stocks
What’s up psychedelic stocks investors?!? Today marked atai Life Science’s (Nasdaq: atai) first-ever conference call, for Quarter 2, 2021. In the conference call, atai Life Sciences gave updates on their varying projects, ranging from attempting to treat depression, to cognitive impairment associated with schizophrenia. They also give insights on atai’s digital medicines division and answer investor’s questions at the end of the call.
This Peter Thiel-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 10+ different projects under their belt, atai is one of the most exciting companies to keep an eye on in the industry.
This conference call can help investors answer the questions: is atai stock a good investment? Will atai go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
#atai #ataiLifeSciences #PsychedelicStocks
Interview With Dr. Steven Mandel
In this episode of the Psychedelic Spotlight podcast, we have the distinct privilege of speaking with one of the foremost experts in ketamine-assisted therapy, Dr. Steven L. Mandel, Founder and President of Ketamine Clinics Los Angeles.
Psilocybin as an Agent for Human and Cultural Development with Jahan Khamsehzadeh Ph.D.
In this episode, Dr. Khamsehzadeh delves into our historical and ancestral relationship to psilocybin and theorizes how mushrooms have impacted the development of the brain.